Thomaspartners’s AbbVie ABBV Stock Holding History

Thomaspartners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2,986	Closed	-$201K	–	109
2015 Q2	$201K	Buy	+2,986	New	+$195K	﹤0.01%	118
2014 Q3	–	Sell	-5,974	Closed	-$337K	–	136
2014 Q2	$337K	Sell	5,974 -595	-9%	-$31.2K	0.01%	102
2014 Q1	$338K	Sell	6,569 -1,185	-15%	-$59.9K	0.01%	107
2013 Q4	$409K	Sell	7,754 -240,196	-97%	-$11.8M	0.01%	101
2013 Q3	$11.1M	Sell	247,950 -191,256	-44%	-$8.48M	0.4%	67
2013 Q2	$20M	Buy	+439,206	New	+$19.2M	0.78%	57

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Thomaspartners's ABBV Position: Q3 2015 in Review

Thomaspartners sold out of AbbVie (ABBV) in Q3 2015, closing a stake of 2,986 shares — an estimated $201K sold.

Thomaspartners first reported a position in ABBV in Q2 2013 and held it in 6 quarters. The position peaked at $20M in Q2 2013. 1,604 funds tracked by Wall St. Rank hold ABBV as of Q3 2015.

Thomaspartners reported no remaining AbbVie position as of Q3 2015 after selling out during the quarter.
Thomaspartners sold 2,986 AbbVie shares in Q3 2015, an estimated $201K.
Thomaspartners first reported a position in AbbVie in Q2 2013 and held it in 6 quarters.
Thomaspartners's AbbVie position peaked at $20M in Q2 2013.
1,604 funds tracked by Wall St. Rank held AbbVie as of Q3 2015.

Based on Thomaspartners's 13F filing for Q3 2015, filed 13 Nov 2015.